C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy
NCT07729826
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Lupus Nephritis (LN)
Systemic Lupus Erythematosus (SLE)
Autoimmune Diseases
Interventions
DRUG:
C-CAR168
Sponsor
AbelZeta Inc.